Hepatitis B Control
Country Profile 2015
Regional Progress

Hepatitis B vaccination coverage, 1990 – 2015

Source: WHO and UNICEF Joint Reporting Form on Immunization
Regional Progress

Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO Regional Office for the Western Pacific 2016. All rights reserved
AMERICAN SAMOA

Demographics

- Total population (2015): 55,538
- Births (2011): 1,287
- Surviving infants (2011): 1,278
- Urban population (2015): 87%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1986-1987
- HepB birth dose introduced: 1991
- Current schedule: 0, 1 month, 12 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: February 2013
  - Decision: <1% in children
  - Decision date: October 2014

2012 Neonatal deliveries

- Total: 99.0%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1990</td>
<td>National</td>
<td>3-4 years</td>
<td>95</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1995</td>
<td>National</td>
<td>7-8 years</td>
<td>432</td>
<td>75%</td>
<td>91%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>1996</td>
<td>National</td>
<td>7-8 years</td>
<td>435</td>
<td>not reported</td>
<td>87%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Tutuila</td>
<td>3-4 years</td>
<td>Community based</td>
<td>93</td>
<td>2.2%</td>
<td>Mahoney JID 2009</td>
</tr>
<tr>
<td>1995</td>
<td>Nationwide</td>
<td>7-8 years</td>
<td>Community based</td>
<td>432</td>
<td>0.5%</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2011</td>
<td>Nationwide</td>
<td>6 years</td>
<td>School based</td>
<td>562</td>
<td>0.2%</td>
<td>Govt American Samoa 2012</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
Demographics

Total population (2015) 23,968,973
Births (2015) 317,650
Surviving infants (2015) 314,448
Urban population (2015) 89%

Hepatitis B vaccine

HepB3 introduced nationwide 2000
HepB birth dose introduced 2000
Current schedule 0, 2 months, 4 months, 6 months
HepB3 type DTP-Hib-HepB-IPV

WHO verification

Status of verifying prevalence targets
Verification started: June 2012
Decision: <1% in children
Decision date: December 2012

2012 Neonatal deliveries

Hepatitis B vaccination coverage

2015 Districts by coverage categories*

Vaccination coverage surveys

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2007 National 12 months 280,874 not reported 94% 92% From National Health Insurance covering 99% of population

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
2002 Nationwide 1-9 years Hospital based 249 0.4% (0.0% - 2.2%) Gidding Vaccine 2007

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
BRUNEI DARUSSALAM

Demographics
- Total population (2015): 417,200
- Births (2015): 6,699
- Surviving infants (2015): 6,455
- Urban population (2015): 77%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-Hib-HepB-IPV

WHO verification
- Status of verifying prevalence targets
- Verification started: March 2013
- Decision: <1% in children
- Decision date: June 2013

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>8-9 years</td>
<td>School based</td>
<td>4513</td>
<td>0.09%</td>
<td></td>
<td>MoH Brunei 2012</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>8-9 years</td>
<td>School based</td>
<td>4513</td>
<td>0.09%</td>
<td>MoH Brunei 2012</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics

- **Total population (2015):** 14,892,374
- **Births (2015):** 381,245
- **Surviving infants (2015):** 344,014
- **Urban population (2015):** 93%

### Hepatitis B vaccine

- **HepB3 introduced nationwide:** 2005
- **HepB birth dose introduced:** 2005
- **Current schedule:** 0, 6 weeks, 14 weeks
- **HepB3 type:** DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets:**
  - **Verification started:** pending
  - **Decision:** n.a.
  - **Decision date:** n.a.

### 2012 Neonatal deliveries

- **29.0%**: Hospital based
- **54.0%**: Home with SBA
- **17.0%**: Home with no SBA
- **2.0%**: Unknown

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>1517</td>
<td>not reported</td>
<td>not reported</td>
<td>78%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-23 months</td>
<td>1068</td>
<td>61%</td>
<td>not reported</td>
<td>56%</td>
<td>Cambodia Socio-Economic Survey 2009 (confirmation method only by card)</td>
</tr>
<tr>
<td>2010</td>
<td>National</td>
<td>12-23 months</td>
<td>1614</td>
<td>73%</td>
<td>84%</td>
<td>84%</td>
<td>DHS Survey: HepB BD 73%, HepB3 85%, DTP3 85% by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>12-23 months</td>
<td>1460</td>
<td>83%</td>
<td>84%</td>
<td>84%</td>
<td>DHS Survey: HepB BD 83%, HepB3 82%, DTP3 82% by 12 months</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>Kg Chhnang</td>
<td>9-17 months</td>
<td>Hospital based</td>
<td>900</td>
<td>2.7%</td>
<td>Report MoH/PATH/AIHI</td>
</tr>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>5 years</td>
<td>Community based</td>
<td>1558</td>
<td>3.5% (2.4% - 4.8%)</td>
<td>Soeung AMTH 2009</td>
</tr>
<tr>
<td>2011</td>
<td>Urban, Rural, Remote</td>
<td>4-5 years</td>
<td>Community based</td>
<td>2429</td>
<td>0.3%, 1.4%, 3.5%</td>
<td>Mao Vaccine 2013</td>
</tr>
</tbody>
</table>

### Abbreviations:
- **DTP3**: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine
- **HepB3**: at least 3 doses of hepatitis B vaccine
- **HBsAg**: hepatitis B surface antigen
- **SBA**: Skilled Birth Attendant
- **Timely HepB BD**: birth dose within 24 hours

### Sources:
- Urban population was derived from World Bank
- 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics
- **Total population (2015):** 1,374,620,000
- **Births (2015):** 16,550,000
- **Surviving infants (2014):** 16,152,165
- **Urban population (2015):** 21%

### Hepatitis B vaccine
- **HepB3 introduced nationwide:** 1992
- **HepB birth dose introduced:** 1992
- **Current schedule:** 0, 1 month, 6 months
- **HepB3 type:** Monovalent

### WHO verification
- **Status of verifying prevalence targets**
  - **Verification started:** February 2012
  - **Decision:** <1% in children
  - **Decision date:** June 2012

### 2012 Neonatal deliveries
- **Health facility: 96.3%**
- **Home with SBA: 3.7%**
- **Home with no SBA:**
- **Unknown:**

### Hepatitis B vaccination coverage
- **Survey year:**
  - 2004: National
    - Ages enrolled: 12-23 months
    - Sample size: 171,188
    - HepB BD %: not reported
    - HepB3 %: 85%
    - DTP3 %: not reported
    - Reference/Notes: The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months
  - 2006: National
    - Ages enrolled: 1 year
    - Sample size: 3,636
    - HepB BD %: 93%
    - HepB3 %: 83%
    - DTP3 %: not reported
    - Reference/Notes: Liang JID 2009; 2005 birth cohort
  - 2008: National
    - Ages enrolled: 12-23 months
    - Sample size: 9,762
    - HepB BD %: not reported
    - HepB3 %: 93%
    - DTP3 %: 91%
    - Reference/Notes: Analysis Report of National Health Services Survey in China

### 2015 Districts by coverage categories
- **% District 2015: HepB3 Timely HepB BD**

### Vaccination coverage surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>National</td>
<td>12-23 months</td>
<td>171,188</td>
<td>not reported</td>
<td>85%</td>
<td>not reported</td>
<td>The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>1 year</td>
<td>3,636</td>
<td>93%</td>
<td>83%</td>
<td>not reported</td>
<td>Liang JID 2009; 2005 birth cohort</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>12-23 months</td>
<td>9,762</td>
<td>not reported</td>
<td>93%</td>
<td>91%</td>
<td>Analysis Report of National Health Services Survey in China</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>1-4 years</td>
<td>Community based</td>
<td>16,376</td>
<td>1.0% (0.8% - 1.2%)</td>
<td>Liang Vaccine 2009</td>
</tr>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>5 years</td>
<td>Community based</td>
<td>2215</td>
<td>1.1% (0.4% - 1.8%)</td>
<td>Liang JID 2009</td>
</tr>
<tr>
<td>2006</td>
<td>Nationwide</td>
<td>6 years</td>
<td>Community based</td>
<td>2356</td>
<td>0.9% (0.4% - 1.5%)</td>
<td>Liang JID 2009</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diptheria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
Demographics

- Total population (2015): 7,305,700
- Births (2015): 59,901
- Surviving infants (2015): No data
- Urban population (2015): 95%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: February 2011
  - Decision: <1% in children
  - Decision date: July 2011

2012 Neonatal deliveries

- Health facility
- Home with SBA
- Home with no SBA
- Unknown

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2009 | National | 2-5 years | 6248 | Not reported | ≥99.5% | >99.8% | MoH Hong Kong 2011

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | Reference/Notes
--- | --- | --- | --- | ---
2009 | National | 2-5 years | 6248 | MoH Hong Kong 2011

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95% CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
2006 | Nationwide | 1-4 years | Laboratory based | 196 | 1% | MoH Hong Kong 2011
2009 | Nationwide | 12-15 years | School based | 1913 | 0.8% (0.4% - 1.2%) | MoH Hong Kong 2011

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
MACAO SAR (CHINA)

Demographics

<table>
<thead>
<tr>
<th>Total population (2015)</th>
<th>646,800</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2015)</td>
<td>7,055</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>7,055</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>100%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1984
- HepB birth dose introduced: 1989
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: April 2008
  - Decision: <1% in children
  - Decision date: August 2008

2012 Neonatal deliveries

- Health facility
- Home with SBA
- Home with no SBA
- Unknown

100.0%

Hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

2015 Districts by coverage categories*

![Graph showing coverage categories]

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>6-9 years</td>
<td>School based</td>
<td>437</td>
<td>0% (0% - 0.7%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>6-9 years</td>
<td>School based</td>
<td>437</td>
<td>0% (0% - 0.7%)</td>
<td>MoH Macao 2008</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS

Demographics

- Total population (2015): 55,070
- Births (2011): 1,025
- Surviving infants (2011): 1,038
- Urban population (2015): 89%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTP-HepB-IPV

2012 Neonatal deliveries

- Health facility
- Home with SBA
- Home with no SBA
- Unknown

Hepatitis B vaccination coverage

2015 Districts by coverage categories

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
1995 | National | 3-4 years | 200 | not reported | 94% | not reported | Mahoney Pac Hth Dialog 1996
2005 | National | 19-35 months | 295 | 100% | 94% | not reported |

Hepatitis B serological surveys

- Sample size: 200
- HBsAg prevalence (95%CI): 0.5%
- Reference/Notes: Durand Pac Hth Dial 1996

- Sample size: 804
- HBsAg prevalence (95%CI): 0.0%
- Reference/Notes: CNMI Healthcare Corp. 2015

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics

- **Total population (2015):** 15,052
- **Births (2015):** 234
- **Surviving infants (2015):** 232
- **Urban population (2015):** 56%

### Hepatitis B vaccine

- **HepB3 introduced nationwide:** 1989
- **HepB birth dose introduced:** 1989
- **Current schedule:** 0, 6 weeks, 3 months, 5 months
- **HepB3 type:** DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets:**
  - Verification started: January 2013
  - Decision: <1% in children
  - Decision date: October 2013

### 2012 Neonatal deliveries

- **Location:** 7 of 11 islands
- **Ages enrolled:** 6 years
- **Sampling base:** School based
- **Sample size:** 265
- **HepB BD %:** 0%
- **HepB3 %:** 0%
- **DTP3 %:** 100%

### Hepatitis B serological surveys

- **Survey year:** 2012
- **Location:** 7 of 11 islands
- **Ages enrolled:** 6 years
- **Sampling base:** School based
- **Sample size:** 265
- **HBsAg prevalence (95%CI):** 0%
- **Reference/Notes:** MoH Cook Islands 2013

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vaccination Coverage (%):</strong></td>
<td><strong>Timely HepB BD</strong></td>
<td><strong>Any HepB BD</strong></td>
<td><strong>HepB3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations

- **DTP3:** 3rd dose of Diphtheria, Tetanus and Pertussis vaccine
- **HepB3:** at least 3 doses of hepatitis B vaccine
- **HBsAg:** hepatitis B surface antigen
- **SBA:** Skilled Birth Attendant
- **Timely HepB BD:** birth dose within 24 hours

### Sources

- Urban Population was derived from World Bank
- 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
### Demographics

<table>
<thead>
<tr>
<th>Total population (2015)</th>
<th>933,073</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2015)</td>
<td>20,236</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>20,072</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>75%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1989
- **HepB birth dose introduced**: 1989
- **Current schedule**: 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type**: DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets**
  - **Verification started**: pending
  - **Decision**: n.a.
  - **Decision date**: n.a.

### 2012 Neonatal deliveries

![Circle diagram showing 99.8% health facility, 0.2% Home with SBA, 0% Home with no SBA, and 0% Unknown.]

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>National</td>
<td>12-23 months</td>
<td>not reported</td>
<td>94%</td>
<td>n.a.</td>
<td>92%</td>
<td>Fiji National EPI Survey</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>630</td>
<td>92%</td>
<td>83%</td>
<td>Fiji Immunization Coverage Survey Report</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>15-26 months</td>
<td>1200</td>
<td>86%</td>
<td>99%</td>
<td>Fiji National Immunisation Coverage Survey</td>
<td></td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>285</td>
<td>0.7%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2008</td>
<td>Sub-national</td>
<td>6 months-5 years</td>
<td>Community based</td>
<td>428</td>
<td>0%</td>
<td>WHO-GE-2009/GE/23(JPN)</td>
</tr>
</tbody>
</table>

### Abbreviations

- DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

### Sources

- Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
FRENCH POLYNESIA

Demographics

Total population (2015): 271,800
Births (2015): 4,146
Surviving infants (2015): no data
Urban population (2015): 54%

Hepatitis B vaccine

HepB3 introduced nationwide: 1992
HepB birth dose introduced: 1992
Current schedule: 0, 2 months, 10 months
HepB3 type: DTP-Hib-HepB-IPV

WHO verification

Status of verifying prevalence targets
Verification started: February 2016
Decision: <1% in children
Decision date: October 2016

2012 Neonatal deliveries

Total population (2015): 271,800
Births (2015): 4,146
Surviving infants (2015): no data
Urban population (2015): 54%

Hepatitis B vaccination coverage

Survey year Location Ages enrolled Sampling base Sample size HepB BD % HepB3 % DTP3 % Reference/Notes

1988 Austral Island 0-11 months Community based 957 2.1% B Trans R Soc Trop 1990
2013-2014 Nationwide 6-7 years School based 1196 0.0% (0.0%-0.5%) Patel Vaccine 2016

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
GUAM

Demographics

<table>
<thead>
<tr>
<th>Total population (2015)</th>
<th>161,785</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2015)</td>
<td>3,367</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>3,319</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>56%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1-2 months, 6-18 months
- HepB3 type: Monovalent

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>National</td>
<td>6 years</td>
<td>School based</td>
<td>1,484</td>
<td>0.0%</td>
<td>Guam DoH &amp; Social Services 2015</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: October 2015
  - Decision: <1% in children
  - Decision date: July 2016

Survey year

- 2015 Districts by coverage categories
- Timely HepB BD
- Any HepB BD
- HepB3

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

2012 Neonatal deliveries

- 12.2% Health facility
- 0.6% Home with SBA
- 12.2% Home with no SBA
- 87.2% Unknown

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
**JAPAN**

### Demographics

- **Total population (2015):** 126,942,000
- **Births (2015):** 1,037,064
- **Surviving infants (2015):** 1,013,979
- **Urban population (2015):** 100%

### Hepatitis B vaccine

- **HepB3 introduced nationwide**
- **Scheduled to start in Oct 2016**
- **HepB birth dose introduced:** If born to HBsAg+ mothers
- **Current schedule:** 2 months, 3 months, 7 months
- **HepB3 type:** Monovalent

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### 2012 Neonatal deliveries

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>Okinawa</td>
<td>1-4 years</td>
<td>School based</td>
<td>1529</td>
<td>0.1%</td>
<td>Hayashi Int J Epi 1990</td>
</tr>
<tr>
<td>1995-1996</td>
<td>Nationwide</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>107,879</td>
<td>0.4% (0.4% - 0.5%)</td>
<td>Furusyo AMTM 1998</td>
</tr>
<tr>
<td>1995-2000</td>
<td>Nationwide</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>582,415</td>
<td>0.23% (0.22% - 0.24%)</td>
<td>Tanaka Interviro 2004</td>
</tr>
<tr>
<td>2009</td>
<td>Iwate prefecture</td>
<td>5-9 years</td>
<td>School based</td>
<td>17,363</td>
<td>0.0% (0.00%-0.04%)</td>
<td>Tanaka Interviro 2011</td>
</tr>
</tbody>
</table>

### Abreviations:

- **DTP3:** 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; **HepB3:** at least 3 doses of hepatitis B vaccine; **HBsAg:** hepatitis B surface antigen; **SBA:** Skilled Birth Attendant; **Timely HepB BD:** birth dose within 24 hours

### Sources:

- Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**Demographics**

- Total population (2015): 114,104
- Urban population (2015): 44%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1995
- HepB birth dose introduced: 1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

**WHO verification**

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

---

**2012 Neonatal deliveries**

- 16.4%
- Health facility
- Home with SBA
- Home with no SBA
- Unknown

---

**Hepatitis B vaccination coverage**

---

**2015 Districts by coverage categories***

---

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>48-59 months</td>
<td>181</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>36-47 months</td>
<td>200</td>
<td>not reported</td>
<td>not reported</td>
<td>42%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>24-35 months</td>
<td>202</td>
<td>not reported</td>
<td>not reported</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-23 months</td>
<td>233</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey: HepB3 58%, DTP3 58% by 12 months</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95% CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>156</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>1249</td>
<td>3.3%</td>
<td>MoH Kiribati 2015</td>
</tr>
</tbody>
</table>

**Abbreviations:**

- DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available; otherwise graph represents DPT3 coverage.
LAO PEOPLE’S DEMOCRATIC REPUBLIC

Demographics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2015)</td>
<td>6,949,000</td>
</tr>
<tr>
<td>Births (2015)</td>
<td>194,026</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>183,962</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>39%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 2001
- HepB birth dose introduced: ~2004
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>828</td>
<td>not reported</td>
<td>not reported</td>
<td>41%</td>
<td>Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months</td>
</tr>
<tr>
<td>2011-2012</td>
<td>National</td>
<td>12-23 months</td>
<td>2141</td>
<td>37%</td>
<td>56%</td>
<td>56%</td>
<td>Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>5981</td>
<td>72%</td>
<td>81%</td>
<td>81%</td>
<td>National Immunization Survey</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HbsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>965</td>
<td>1.7% (0.8%-2.6%)</td>
<td>Xeuatvongsa PloS ONE 2014</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HbsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DTP3 coverage.
**Demographics**
- Total population (2015): 30,485,200
- Births (2015): 511,865
- Surviving infants (2015): 511,865
- Urban population (2015): 75%

**Hepatitis B vaccine**
- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

**WHO verification**
- Status of verifying prevalence targets
  - Verification started: March 2011
  - Decision: <1% in children
  - Decision date: July 2011

**2012 Neonatal deliveries**
- 1.4%
- 98.1%

**Vaccination coverage surveys**

**Hepatitis B vaccination coverage**

**2015 Districts by coverage categories**

**Hepatitis B serological surveys**

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Surviving infants was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
FEDERATED STATES OF MICRONESIA

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2015)</td>
<td>102,624</td>
</tr>
<tr>
<td>Births (2015)</td>
<td>2,290</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>2,243</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>22%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-HepB-IPV

WHO verification

- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

2012 Neonatal deliveries

- Health facility: 80.0%
- Home with SBA: 20.0%
- Home with no SBA: 0%
- Unknown: 0%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>National</td>
<td>2 years</td>
<td>16,391</td>
<td>not reported</td>
<td>84%</td>
<td>not reported</td>
<td>Manea PH Reports 1992</td>
</tr>
<tr>
<td>1992</td>
<td>Chuuk</td>
<td>2 years</td>
<td>544</td>
<td>not reported</td>
<td>40%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1994</td>
<td>Pohnpei</td>
<td>3-4 years</td>
<td>364</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>2000</td>
<td>Chuuk</td>
<td>2-6 years</td>
<td>365</td>
<td>50%</td>
<td>87%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2005</td>
<td>Pohnpei</td>
<td>2-9 years</td>
<td>478</td>
<td>87%</td>
<td>90%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>2-9 years</td>
<td>432</td>
<td>75%</td>
<td>91%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Chuuk</td>
<td>2-6 years</td>
<td>Hospital based</td>
<td>362</td>
<td>2.5%</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2005</td>
<td>Pohnpei</td>
<td>2-6 years</td>
<td>Hospital based</td>
<td>478</td>
<td>1.5%</td>
<td>Bialek PID 2010</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
### Demographics
- Total population (2015): 3,129,495
- Births (2015): 81,715
- Surviving infants (2015): 79,647
- Urban population (2015): 72%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1991
- HepB birth dose introduced: 1991
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

### WHO verification
- Status of verifying prevalence targets
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: July 2012

### Hepatitis B vaccination coverage

#### 2015 Districts by coverage categories*

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>National</td>
<td>7-12 years</td>
<td>School based</td>
<td>1145</td>
<td>5.2%</td>
<td>Davaalkham PI 2007</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>4 years</td>
<td>Community based</td>
<td>5894</td>
<td>0.34%</td>
<td>MoH Mongolia 2011</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>National</td>
<td>7-12 years</td>
<td>School based</td>
<td>1145</td>
<td>5.2%</td>
<td>Davaalkham PI 2007</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>4 years</td>
<td>Community based</td>
<td>5894</td>
<td>0.34%</td>
<td>MoH Mongolia 2011</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diptheria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
NAURU

Demographics

<table>
<thead>
<tr>
<th>Total population (2015)</th>
<th>10 084</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2015)</td>
<td>377</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>372</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>100%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

<table>
<thead>
<tr>
<th>HepB3 introduced nationwide</th>
<th>1983</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB birth dose introduced</td>
<td>Yes, introduction year unknown</td>
</tr>
<tr>
<td>Current schedule</td>
<td>0, 6 weeks, 10 weeks, 14 weeks</td>
</tr>
<tr>
<td>HepB3 type</td>
<td>DTP-Hib-HepB</td>
</tr>
</tbody>
</table>

WHO verification

Status of verifying prevalence targets

<table>
<thead>
<tr>
<th>Verification started</th>
<th>pending</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decision</td>
<td>n.a.</td>
</tr>
<tr>
<td>Decision date</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

2012 Neonatal deliveries

97.4%

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---------|--------------|-------------|-----------|---------|--------|-------------------

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
---|---------|--------------|---------------|-------------|-------------------------|-------------------

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

<table>
<thead>
<tr>
<th>Total population (2014)</th>
<th>268 767</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2014)</td>
<td>4 425</td>
</tr>
<tr>
<td>Surviving infants (2014)</td>
<td>4 352</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>70%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

**WHO verification**

- Status of verifying prevalence targets: Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**2012 Neonatal deliveries**

- Health facility: 87.6%
- Home with SBA: 4.4%
- Home with no SBA: 8.0%

**Hepatitis B vaccination coverage**

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>Any HepB BD</th>
<th>HepB3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>2012</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>2013</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>2014</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>2015</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
</tbody>
</table>

**2015 Districts by coverage categories**

- District 2015: HepB3

---

**Abbreviations**

- DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

**Sources**

- Urban Population was derived from World Bank
- 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles
- All remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

---

**References/Notes**

- Urban Population was derived from World Bank
- 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles
- All remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
NEW ZEALAND

Demographics

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2015)</td>
<td>4,649,700</td>
</tr>
<tr>
<td>Births (2015)</td>
<td>61,328</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>61,038</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>86%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: If born to HBsAg+ mothers
- Current schedule: 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

2012 Neonatal deliveries

- Health facility: 95.3%
- Home with SBA: 4.7%
- Home with no SBA: 0%
- Unknown: 0%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DPT3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12 months</td>
<td>1563</td>
<td>72%</td>
<td>82%</td>
<td>85%</td>
<td>MoH; 87% HepB3 by 2 years</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>North Islands</td>
<td>6 years</td>
<td>Health facility</td>
<td>466</td>
<td>0.2% (0.0% - 1.2%)</td>
<td>Weir R. MoH New Zealand 2009</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets:
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: September 2012

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

- Total population (2015): 1,776
- Births (2015): 30
- Surviving infants (2015): 30
- Urban population (2015): 43%

### Hepatitis B vaccine

- HepB3 introduced nationwide: 1986
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

### WHO verification

- Status of verifying prevalence targets:
  - Verification started: November 2015
  - Decision: n.a.
  - Decision date: n.a.

### 2012 Neonatal deliveries

- Survey year: Nationwide
- Location: School based
- Ages enrolled: 5-12 years
- Sample size: 183
- HBsAg prevalence (95%CI): 0.0%
- Reference/Notes: Niue Health Department 2015

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2015 Districts by coverage categories *

- District 2015

### Vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>Nationwide</td>
<td>5-12 years</td>
<td>School based</td>
<td>183</td>
<td>0.0%</td>
<td>Niue Health Department 2015</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
PALAU

Demographics

- Total population (2015): 7261
- Births (2015): 301
- Surviving infants (2015): 301
- Urban population (2015): 87%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 6 months
- HepB3 type: DTP-HepB-IPV and monovalent

WHO verification

- Status of verifying prevalence targets:
  - Verification started: January 2013
  - Decision: <1% in children
  - Decision date: May 2013

2012 Neonatal deliveries

- Health facility: 100.0%
- Home with SBA
- Home with no SBA
- Unknown

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>10-11 years</td>
<td>192</td>
<td>100%</td>
<td>85%</td>
<td>not reported</td>
<td>Bialek ISVHL D P351 2006</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>Nationwide</td>
<td>10-11 years</td>
<td>Community based</td>
<td>192</td>
<td>0%</td>
<td>Bialek ISVHL D P351 2006</td>
</tr>
<tr>
<td>2008</td>
<td>Main Island</td>
<td>5-7 years</td>
<td>School based</td>
<td>143</td>
<td></td>
<td>MoH Palau 2013</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

Total population (2015) 8 235 782
Births (2015) 263 545
Surviving infants (2015) 248 576
Urban population (2015) 13%

2012 Neonatal deliveries

Hepatitis B vaccine

HepB3 introduced nationwide 1989
HepB birth dose introduced ~2003
Current schedule 0, 1 month, 2 months, 3 months
HepB3 type DTP-Hib-HepB

WHO verification

Status of verifying prevalence targets
Verification started: pending
Decision: n.a.
Decision date: n.a.

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005-2006</td>
<td>National</td>
<td>12-23 months</td>
<td>783</td>
<td>not reported</td>
<td>not reported</td>
<td>71%</td>
<td>National Immunization Coverage Survey</td>
</tr>
<tr>
<td>2005-2006</td>
<td>National</td>
<td>12-23 months</td>
<td>774</td>
<td>not reported</td>
<td>73%</td>
<td>not reported</td>
<td>National Immunization Coverage Survey</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989-1990</td>
<td>Port Moresby</td>
<td>3-5 months</td>
<td>Hospital Based</td>
<td>31</td>
<td>13%</td>
<td>Nemba ATPaed. 1993</td>
</tr>
<tr>
<td>2012-2013</td>
<td>National</td>
<td>4-6 years</td>
<td>Community based</td>
<td>2109</td>
<td>2.3%</td>
<td>Kitau ASTMH 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**PHILIPPINES**

### Demographics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2015)</td>
<td>101,771,950</td>
</tr>
<tr>
<td>Births (2015)</td>
<td>2,747,843</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>2,679,147</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>44%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

<table>
<thead>
<tr>
<th>Event</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3 introduced nationwide</td>
<td>1991</td>
</tr>
<tr>
<td>HepB birth dose introduced</td>
<td>2007</td>
</tr>
</tbody>
</table>

### Current schedule

- 0, 6 weeks, 10 weeks, 14 weeks

### HepB3 type

- DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### 2012 Neonatal deliveries

- Health facility: 37.8%
- Home with SBA: 44.0%
- Home with no SBA: 18.2%
- Unknown: 6.0%

### Hepatitis B vaccination coverage

#### 2015 Districts by coverage categories *

**Abbreviations**: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
## Demographics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2015)</td>
<td>51,529,338</td>
</tr>
<tr>
<td>Births (2015)</td>
<td>435,969</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>433,930</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>83%</td>
</tr>
</tbody>
</table>

## Hepatitis B vaccine

- HepB3 introduced nationwide: 1983
- HepB birth dose introduced: 1983
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

## WHO verification

- Status of verifying prevalence targets
  - Verification started: January 2008
  - Decision: <1% in children
  - Decision date: June 2008

## 2012 Neonatal deliveries

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>0-3 years</td>
<td>Community based</td>
<td>7040</td>
<td>0.1%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

## Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>National</td>
<td>0-6 years</td>
<td>1026</td>
<td>100%</td>
<td>93%</td>
<td>95%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>19-35 months</td>
<td>not reported</td>
<td>not reported</td>
<td>99%</td>
<td>99%</td>
<td>2009 Korea National Immunization Survey (Confirmation method NA)</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>0-3 years</td>
<td>7040</td>
<td>99%</td>
<td>98%</td>
<td>93%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

## Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Nationwide</td>
<td>10-14 years</td>
<td>Community based</td>
<td>594</td>
<td>0.2% (0.0% - 0.6%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2007</td>
<td>Nationwide</td>
<td>4-6 years</td>
<td>Hospital based</td>
<td>2920</td>
<td>0.2% (0.0% - 0.4%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2014</td>
<td>Nationwide</td>
<td>10-18 years</td>
<td>Community based</td>
<td>510</td>
<td>0.1%</td>
<td>KNHANES 2014</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
**Demographics**

- Total population (2015): 54,880
- Births (2015): 1,140
- Surviving infants (2015): 1,135
- Urban population (2015): 73%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1990s
- HepB birth dose introduced: 1998
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-HepB-IPV

**WHO verification**

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**2012 Neonatal deliveries**

- Health facility: 2.0%
- Home with SBA: 1.0%
- Home with no SBA: 97.0%

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>0-24 months</td>
<td>115</td>
<td>not reported</td>
<td>86%</td>
<td>65%</td>
<td>RMI Community Survey 2006: confirmation method by card only</td>
</tr>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>331</td>
<td>49%</td>
<td>93%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>not reported</td>
<td>214</td>
<td>not reported</td>
<td>not reported</td>
<td>17% (for age 48-59M); 32% (for age 36-47M)</td>
<td>DHS Survey 2007: DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>24-35 months</td>
<td>207</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey 2007: DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>249</td>
<td>not reported</td>
<td>not reported</td>
<td>48%</td>
<td>DHS Survey; DTP3 38% by 12 months</td>
</tr>
</tbody>
</table>

**2015 Districts by coverage categories**

- Timely HepB BD
- Any HepB BD
- HepB3

<table>
<thead>
<tr>
<th>District</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;50%</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>0-24 months</td>
<td>115</td>
<td>not reported</td>
<td>86%</td>
<td>65%</td>
<td>RMI Community Survey 2006: confirmation method by card only</td>
</tr>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>331</td>
<td>49%</td>
<td>93%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>not reported</td>
<td>214</td>
<td>not reported</td>
<td>not reported</td>
<td>17% (for age 48-59M); 32% (for age 36-47M)</td>
<td>DHS Survey 2007: DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>24-35 months</td>
<td>207</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey 2007: DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>249</td>
<td>not reported</td>
<td>not reported</td>
<td>48%</td>
<td>DHS Survey; DTP3 38% by 12 months</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>School based</td>
<td>331</td>
<td>1.8% (0.4% - 3.3%)</td>
<td>Bialek PID 2010</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:**
- Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2015): 192,598
- Births (2015): 5,915
- Surviving infants (2015): 5,624
- Urban population (2015): 19%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

2012 Neonatal deliveries

- Health facility: 81.0%
- Home with SBA: 19.0%
- Home with no SBA: 0.0%
- Unknown: 0.0%

Hepatitis B vaccination coverage

2015 Districts by coverage categories

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2009 | National | 12-24 months | 321 | 70% | not reported | not reported | DHS Survey
2009 | National | 18-29 months | 321 | not reported | not reported | 38% | DHS Survey: 37% DTP3 by 12 months
2014 | National | 48-59 months | 559 | 75% | 45% | 45% | DHS Survey; by 12 months
2014 | National | 36-47 months | 685 | 81% | 50% | 50% | DHS Survey; by 12 months
2014 | National | 24-35 months | 680 | 82% | 54% | 54% | DHS Survey; by 12 months
2015 | National | 12-23 months | 674 | 84% | 64% | 64% | DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3
2015 | National | 18-29 months | 666 | 83% | 64% | 64% | DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
2014 | Nationwide | 5-6 years | School based | 1776 | 0.11% | MoH Samoa 2015

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
SINGAPORE

Demographics

- Total population (2014): 3,870,739
- Births (2014): 33,087
- Surviving infants (2014): 33,087
- Urban population (2015): 100%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: 1987
- Current schedule: 0, 1 month, 5-6 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets:
  - Verification started: April 2015
  - Decision: <1% in children
  - Decision date: October 2015

2012 Neonatal deliveries

- Health facility: 0.3%
- Home with SBA: 99.7%
- Home with no SBA: not reported
- Unknown: not reported

Hepatitis B vaccination coverage

- 2015 Districts by coverage categories

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>2 years</td>
<td>31,778</td>
<td>not reported</td>
<td>94%-96%</td>
<td>97%</td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998-1999</td>
<td>National</td>
<td>0-4 years</td>
<td>not reported</td>
<td>229</td>
<td>0%</td>
<td>Epi News Bull SNG 2000</td>
</tr>
<tr>
<td>2008-2010</td>
<td>Two public hospitals</td>
<td>1-17 years</td>
<td>Hospital based</td>
<td>1,200</td>
<td>0.3% (0.1%-0.9%)</td>
<td>Ang J Med Virol 2013</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
### Demographics

- **Total population (2015):** 592,206
- **Births (2015):** 18,450
- **Surviving infants (2015):** 17,897
- **Urban population (2015):** 22%

### Hepatitis B vaccine

- **HepB3 introduced nationwide:** 1990
- **HepB birth dose introduced:** ~2005
- **Current schedule:** 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type:** DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets:**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### 2012 Neonatal deliveries

- **Survey year:** 2006-2007
- **Location:** National
- **Ages enrolled:** 48-59 months, 36-47 months, 24-35 months, 12-23 months
- **Sample size:** 477, 515, 533, 535
- **HepB BD %:** not reported
- **HepB3 %:** not reported
- **DTP3 %:** 72%, 81%, 80%, 88%
- **Reference/Notes:** DHS Survey (DTP3 by 12 months)

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>48-59 months</td>
<td>477</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>36-47 months</td>
<td>515</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>24-35 months</td>
<td>533</td>
<td>not reported</td>
<td>not reported</td>
<td>80%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>12-23 months</td>
<td>535</td>
<td>not reported</td>
<td>not reported</td>
<td>88%</td>
<td>DHS Survey (87% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Guadalcanal Islands</td>
<td>0-9 years</td>
<td>Hospital based</td>
<td>115</td>
<td>13%</td>
<td>Furusyo Am J Trop 1999</td>
</tr>
</tbody>
</table>

### Abbreviations:
- **DTP:** Diphteria, Tetanus and Pertussis vaccine
- **HepB:** Hepatitis B vaccine
- **HBsAg:** Hepatitis B surface antigen
- **SBA:** Skilled Birth Attendant
- **Timely HepB BD:** Birth dose within 24 hours

### Sources:
- Urban Population was derived from World Bank
- 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
TOKELAU

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Data (2015)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>1383</td>
</tr>
<tr>
<td>Births</td>
<td>30</td>
</tr>
<tr>
<td>Surviving infants</td>
<td>29</td>
</tr>
<tr>
<td>Urban population</td>
<td>0%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: 1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>Nationwide</td>
<td>6-12 years</td>
<td>171</td>
<td>0.0%</td>
<td></td>
<td></td>
<td>MoH Tokelau 2015</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets:
  - Verification started: May 2015
  - Decision: <1% in children
  - Decision date: July 2016

2012 Neonatal deliveries

- Health facility
- Home with SBA
- Home with no SBA
- Unknown

2015 Districts by coverage categories*

<table>
<thead>
<tr>
<th>District 2015</th>
<th>HepB3</th>
<th>Timely HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Survey year        | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>Nationwide</td>
<td>6-12 years</td>
<td>School based</td>
<td>171</td>
<td>0.0%</td>
<td>MoH Tokelau 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2014): 109,418
- Births (2014): 2,744
- Surviving infants (2014): 2,917
- Urban population (2014): 24%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
  - Verification started: May 2011
  - Decision: <2% in children
  - Decision date: January 2012

2012 Neonatal deliveries

- Health facility: 98.0%
- Home with SBA: 0.4%
- Home with no SBA: 1.6%
- Unknown: 0.0%

2015 Districts by coverage categories

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HepB %</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>12-23 months</td>
<td></td>
<td>114</td>
<td>not reported</td>
<td>94%</td>
<td>Evaluation of Immunization Program of the Kingdom of Tonga</td>
</tr>
<tr>
<td>2005</td>
<td>Tongatapu hospital</td>
<td>6-59 months</td>
<td></td>
<td>445</td>
<td>92%</td>
<td>98%</td>
<td>Danielsson Vaccine 2009</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>48-59 months</td>
<td></td>
<td>302</td>
<td>not reported</td>
<td>61%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>36-47 months</td>
<td></td>
<td>334</td>
<td>59%</td>
<td>59%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>24-35 months</td>
<td></td>
<td>383</td>
<td>not reported</td>
<td>60%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>12-23 months</td>
<td></td>
<td>307</td>
<td>not reported</td>
<td>66%</td>
<td>DHS Survey (65% HepB3 and 65% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>211</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2005</td>
<td>Main Island</td>
<td>6-59 months</td>
<td>Hospital based</td>
<td>375</td>
<td>0.8% (0.2% - 2.5%)</td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
TUVALU

Demographics
- Total population (2012): 10,837
- Births (2012): 265
- Surviving infants (2012): 265
- Urban population (2012): 60%

Hepatitis B vaccine
- HepB3 introduced nationwide: Yes, introduction year unknown
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification
- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

2012 Neonatal deliveries
- Health facility
- Home with SBA
- Home with no SBA
- Unknown

2015 Districts by coverage categories*

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---|---|---|---|---|---|---
2007 | National | 48-59 months | 75 | not reported | not reported | 59% | DHS Survey (DTP3 by 18 months)
2007 | National | 36-47 months | 84 | not reported | not reported | 57% | DHS Survey (DTP3 by 18 months)
2007 | National | 24-35 months | 89 | not reported | not reported | 60% | DHS Survey (DTP3 by 18 months)
2007 | National | 18-29 months | 80 | not reported | not reported | 62% | DHS Survey (60% DTP3 by 18 months)

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
---|---|---|---|---|---|---
1976 | Fanafuti | 10-19 years | Community based | 181 | 11% | Gust. JID 1979

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF. Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

<table>
<thead>
<tr>
<th>Total population (2015)</th>
<th>267 184</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2015)</td>
<td>8 283</td>
</tr>
<tr>
<td>Surviving infants (2015)</td>
<td>8 051</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>26%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1989-1990
- **HepB birth dose introduced**: 1989-1990
- **Current schedule**: 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type**: DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### 2012 Neonatal deliveries

- **Survey year**: 2012
- **Location**: National
- **Ages enrolled**: 12-23 months
- **Sample size**: 303
- **HepB BD %**: not reported
- **HepB3 %**: 55%
- **DTP3 %**: 55%
- **Reference/Notes**: DHS Survey; by 12 months 49% HepB3, 49% DTP3

### Hepatitis B vaccination coverage

- **Survey year**: 2011-2015
- **Location**: National
- **Ages enrolled**: 12-23 months
- **Sample size**: 359
- **HepB BD %**: 59%
- **HepB3 %**: 63%
- **DTP3 %**: 55%
- **Reference/Notes**: MICS; by 12 months 55% HepB3, 58% DTP3

### 2015 Districts by coverage categories*

- **<50%**: 0
- **50%-79%**: 0
- **80%-89%**: 20
- **90%-94%**: 40
- **>94%**: 60

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>359</td>
<td>not reported</td>
<td>59%</td>
<td>63%</td>
<td>MICS; by 12 months 55% HepB3, 58% DTP3</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>12-23 months</td>
<td>303</td>
<td>not reported</td>
<td>55%</td>
<td>55%</td>
<td>DHS Survey; by 12 months 49% HepB3, 49% DTP3</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Emao or Nguna</td>
<td>12-18 months</td>
<td>Community based</td>
<td>112</td>
<td>17%</td>
<td>Maher Med J Aust 1991</td>
</tr>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>132</td>
<td>3.0%</td>
<td>Wilson Vaccine 2000</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
VIET NAM

Demographics

- Total population (2015): 91,583,000
- Births (2015): 1,753,504
- Surviving infants (2015): 1,753,504
- Urban population (2015): 34%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1997
- HepB birth dose introduced: 2005
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys

- Survey year: 2012
- Location: National
- Ages enrolled: 12-24 months
- Sample size: 457
- HepB BD %: not reported
- HepB3 %: not reported
- DTP3 %: 72%
- Reference/Notes: DHS Survey

Hepatitis B serological surveys

- Survey year: 1998
- Location: Thanh Hoa
- Ages enrolled: 9-18 months
- Sampling base: Community based
- Sample size: 536
- HBsAg prevalence (95%CI): 12.5%
- Reference/Notes: Hipgrave AJTMH 2003

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

2012 Neonatal deliveries

- Health facility: 5.6%
- Home with SBA: 94.4%

2015 Districts by coverage categories*

Survey year

- 2011
- 2012
- 2013
- 2014
- 2015

Vaccination Coverage (%)

- Timely HepB BD
- Any HepB BD
- HepB3

Vaccination Coverage (%)

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

Vaccination coverage surveys

Hepatitis B vaccination coverage

WHO verification

2012 Neonatal deliveries

Hepatitis B serological surveys

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization